685 European multi-disciplinary tumour boards within the EURACAN network increasingly support management of patients with rare gynaecological tumours: results from 2017–2023 activity

• Published in: International journal of gynecological cancer Vol. 34; no. Suppl 1; pp. A551 - A552
• Main Authors: Bergamini, Alice, Joneborg, Ulrika, Marquina, Gloria, Grassi, Elisa, Wallin, Emelie, Casado, Antonio, Solheim, Olesia, Sassu, Carolina Maria, Lok, Christianne AR, Bini, Marta, Pautier, Patricia, Kridelka, Frédéric, Sehouli, Jalid, Nieuwenhuysen, Els Van, Coulter, John, Bolze, Pierre-Adrien, Lebreton, Coriolan, Piek, Jurgen MJ, Ray-Coquard, Isabelle, Seckl, Michael
• Format: Journal Article
• Language: English
• Published: Oxford BMJ Publishing Group Ltd 10.03.2024; BMJ Publishing Group LTD
• Subjects: Cancer; Gynecological cancer; Gynecology; Poster and E-Posters
• ISSN: 1048-891X; 1525-1438
• DOI: 10.1136/ijgc-2024-ESGO.1082

Introduction/BackgroundThe European Reference Network for Rare Adult Cancers (EURACAN) G2 domain deals with rare gynaecological cancers. Within this domain, virtual multi-disciplinary tumour boards (MDTs) were implemented in 2017 to advise on clinical management of patients. Here, we update on the 6-year activity in terms of participation and treatment recommendations.MethodologyEURACAN G2 cross-border MDTs were organized monthly since November 2017 by Karolinska University Hospital, Stockholm, Sweden1. From March 2021 to April 2023, the MDTs were coordinated by Ospedale San Raffaele, Milan, Italy and since March 2023 by Hospital Clinico San Carlos, Madrid, Spain. A standardized form was used for collecting patient data and a summary of cases was circulated to all participants prior to the MDTs. The outcomes, including recommendations for further investigations and treatment, were distributed following each MDT to validate the proposal. The MDT background data and outcomes of discussions were registered in a prospective database.ResultsBetween November 2017 and October 2023, 67 MDTs were organized with participants from 18 countries and 20 EURACAN centers. 260 individual patients were discussed (median 4 patients/session, range 1–12). Background data are presented in table 1. The number of cases discussed has increased over the years (median/year=46, range 29–82); the number of participants/session has increased over time (median 12, range 11–15). The MDT discussions resulted in a recommendation for pathological review and sequencing in 24% and 9.6% of cases, respectively. Surveillance instead of oncological treatment was recommended to 17% of cases, while off-label treatment and inclusion in a clinical trial were recommended in 12% and 8.5% of cases, respectively. For 58.7% of patients, new treatment opportunities were suggested, compared to the locally proposed management.ConclusionEURACAN G2 domain MDTs increasingly offers an opportunity for clinical support and formulation of treatment strategies for physicians to manage patients with rare gynecological cancers.DisclosuresNo disclosures.Abstract 685 Table 1